# US 2025/0360207 A1 · Methods for treating lupus nephritis using fcrn antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0360207 A1
- Document ID: US20250360207A1
- Status: Published application
- Kind: A1
- Application number: 19/200,764
- Filed: 2025-05-07
- Published: 2025-11-27
- Earliest claimed: 2022-11-07
- Assignees: argenx BV
- Applicants: argenx BV
- Inventors: Tim Van Hauwermeiren; Peter Verheesen; Magdalena Sips
- Web page: https://patentgrep.com/patent/US20250360207A1

## CPC

- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 39/39541: {against normal tissues, cells}
- A61K 31/365: Lactones
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 13/12: of the kidneys
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/52: Constant or Fc region; Isotype
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are methods of treating lupus nephritis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of lupus nephritis and for use in the manufacture of a medicament for the treatment of lupus nephritis are also provided herein.

## Claims

### Claim 1

A method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject an effective amount of a human neonatal Fc receptor (FcRn) antagonist, wherein the FcRn antagonist comprises or consists of a variant Fc region or FcRn binding fragment thereof.

### Claim at position 2

2-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the variant Fc region comprises or consists of a first Fc domain and a second Fc domain which form a homodimer or heterodimer, wherein the first Fc domain and/or the second Fc domain comprise amino acids Y, T, E, K, and F at EU positions 252, 254, 256, 433, and 434, respectively.

### Claim 7

(canceled)

### Claim 8 (depends on 6)

The method of claim 6, wherein the first Fc domain and/or the second Fc domain comprise amino acids Y, T, E, K, F, and Y at EU positions 252, 254, 256, 433, 434, and 436, respectively.

### Claim 9 (depends on 6)

The method of claim 6, wherein the first Fc domain and/or the second Fc domain comprise an amino acid sequence independently selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 30.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the FcRn antagonist is efgartigimod.

### Claim at position 9

12-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the FcRn antagonist is administered intravenously at a dose of 10 mg/kg to 30 mg/kg once weekly or once every two weeks.

### Claim 15 (depends on 1)

The method of claim 1, wherein the FcRn antagonist is administered intravenously at a dose of 10 mg/kg once weekly.

### Claim 16 (depends on 1)

The method of claim 1, wherein the FcRn antagonist is administered subcutaneously at a fixed dose of 750 mg to 3000 mg once weekly, once every two weeks, once every three weeks, once every four weeks, or once monthly.

### Claim at position 13

17-22. (canceled)

### Claim 23 (depends on 1)

The method of claim 1, further comprising administering to the subject an effective amount of a glucocorticoid, mycophenolate mofetil (MMF), mycophenolic acid (MPA), an angiotensin-converting enzyme inhibitor (ACEi), an angiotensin receptor blocker (ARB), hydroxychloroquine, a B-lymphocyte targeting agent, or any combination thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the glucocorticoid is methylprednisolone or prednisone.

### Claim at position 16

25-37. (canceled)

### Claim 38

A method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject an effective amount of an FcRn antagonist within 60 days of the subject receiving an induction therapy for lupus nephritis.

### Claim 39 (depends on 38)

The method of claim 38, wherein the induction therapy comprises administering to the subject an effective amount of a glucocorticoid.

### Claim 40 (depends on 38)

The method of claim 38, wherein the induction therapy comprises administering to the subject an effective amount of methylprednisolone.

### Claim 41 (depends on 40)

The method of claim 40, wherein the methylprednisolone is administered intravenously at a dose of 250 mg to 500 mg once a day for 1 to 3 days.

### Claim at position 21

42-43. (canceled)

### Claim 44 (depends on 38)

The method of claim 38, wherein the induction therapy comprises administering prednisone to the subject.

### Claim 45 (depends on 44)

The method of claim 44, wherein the prednisone is administered orally at a dose of 10 mg/day to 60 mg/day.

### Claim 46

(canceled)

### Claim 47 (depends on 44)

The method of claim 44, wherein when the subject is administered the FcRn antagonist, the dose of prednisone is tapered over 12 weeks to a dose of 7.5 mg/day.

### Claim 48 (depends on 39)

The method of claim 39, wherein the induction therapy further comprises administering to the subject a daily dose of an effective amount of MMF or MPA.

### Claim 49 (depends on 48)

The method of claim 48, wherein the daily dose of MMF or MPA is up-titrated to 1.5 g/day to 2 g/day in divided doses within 4 weeks.

### Claim 50 (depends on 39)

The method of claim 39, wherein the induction therapy further comprises administering to the subject a dose of an effective amount of hydroxychloroquine or a B-lymphocyte targeting agent.

### Claim at position 29

51-55. (canceled)

### Claim 56 (depends on 1)

The method of claim 1, wherein after administering the FcRn antagonist to the subject, the subject exhibits a post-administration estimated glomerular filtration rate (eGFR) of at least 60 mL/min/1.73 m2 or that is less than 20% reduced as compared to a baseline eGFR obtained from the subject prior to administering the FcRn antagonist.

### Claim at position 31

57-58. (canceled)

### Claim 59 (depends on 1)

The method of claim 1, wherein after administering the FcRn antagonist to the subject, the subject exhibits a post-administration estimated glomerular filtration rate (eGFR) of at least 90 mL/min/1.73 m2 or that is less than 10% reduced as compared to a baseline eGFR obtained from the subject prior to administering the FcRn antagonist.

### Claim at position 33

60-61. (canceled)

### Claim 62 (depends on 1)

The method of claim 1, wherein after administering the FcRn antagonist to the subject, the subject exhibits a post-administration urine protein creatinine ratio (UPCR) of at most 0.5 mg/mg.

### Claim 63 (depends on 1)

The method of claim 1, wherein after administering the FcRn antagonist to the subject, the subject exhibits a post-administration UPCR that is at least 50% reduced as compared to a baseline UPCR obtained from the subject prior to administering the FcRn antagonist, and wherein if the baseline UPCR is at most 3 mg/mg, then the post-administration UPCR is less than 1 mg/mg or if the baseline UPCR is greater than 3 mg/mg, then the post-administration UPCR is less than 3 mg/mg.

### Claim at position 36

64-65. (canceled)

### Claim 66 (depends on 1)

The method of claim 1, wherein after administering the FcRn antagonist to the subject, the subject exhibits a post-administration Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K score that is reduced as compared to a baseline SLEDAI-2K score obtained from the subject prior to administering the FcRn antagonist.

### Claim 67

(canceled)

### Claim 68 (depends on 1)

The method of claim 1, wherein after administering the FcRn antagonist to the subject, the subject exhibits a post-administration level of a serum autoantibody that is reduced as compared to a baseline level of the serum autoantibody obtained from the subject prior to administering the FcRn antagonist.

### Claim at position 40

69-71. (canceled)

### Claim 72 (depends on 1)

The method of claim 1, wherein after administering the FcRn antagonist to the subject, the subject exhibits a post-administration level of a serum complement that is reduced as compared to a baseline level of the serum complement obtained from the subject prior to administering the FcRn antagonist.

### Claim at position 42

73-89. (canceled)
